论文部分内容阅读
目的分析自体造血干细胞移植对T细胞淋巴瘤的疗效及预后。方法回顾性分析20例确诊的T细胞淋巴瘤的临床资料,20例患者均采用自体干细胞移植,MAG方案动员干细胞,BEAM方案预处理。结果(1)所有患者移植后造血功能均顺利重建,中性粒细胞恢复至0.5×109/L,需时(10.50±1.93)d,血小板恢复至20×109/L,需时(12.05±3.03)d;(2)3年疾病预期无进展生存率为88%,无移植治疗相关死亡病例,复发率15%。(3)具有高LDH、IPI≥2分、结外侵犯等危险因素的患者在自体干细胞移植后3年的无疾病进展生存率都比不具有以上高危因素的低。结论自体干细胞移植治疗高危T细胞淋巴瘤安全有效,造血重建顺利。
Objective To analyze the curative effect and prognosis of T-cell lymphoma with autologous hematopoietic stem cell transplantation. Methods The clinical data of 20 patients diagnosed T-cell lymphoma were retrospectively analyzed. All 20 patients were treated with autologous stem cell transplantation and the MAG program was used to mobilize stem cells and pretreatment with BEAM protocol. Results (1) The hematopoietic function of all the patients was successfully reconstructed. The neutrophil recovered to 0.5 × 109 / L, the time required was 10.50 ± 1.93 days, the platelet returned to 20 × 109 / L, the time required was 12.05 ± 3.03 ) d; (2) Prognosis of progression-free survival at 3 years were 88%, with no deaths associated with transplant treatment and a recurrence rate of 15%. (3) Patients with risk factors such as high LDH, IPI≥2 points and extranodal invasion had no disease progression-free survival at 3 years after autologous stem cell transplantation than those without high risk factors. Conclusion Autologous stem cell transplantation for the treatment of high-risk T-cell lymphoma is safe and effective, and the hematopoietic reconstitution is successful.